

Amendment to the Specification

Please amend the specification by amending the paragraph beginning on page 17 at line 22 as follows:

Other fragments and modified sequences of GLP-1 are known in the art (U.S. Patent No. 5,614,492; U.S. Patent No. 5,545,618; European Patent Application, Publication No. EP 0658568 A1; WO 93/25579). Similar fragments and modified sequences of exendin-4 can be easily extrapolated. It is expected that ~~the following residues in GLP-1 (residue number in superscript) and exendin-4 (residue number in parentheses and superscript) should be included in a fragment since these residues are highly conserved and are important for receptor binding:~~ $H^{7(1)}, G^{10(4)}, F^{12(6)}, T^{13(7)}, D^{15(9)}$ (a) the following five residues of GLP-1, an H residue at position 7; a G residue at position 10; an F residue at position 12; a T residue at position 13 and a D residue at position 15, and (b) the following five residues of exendin-4, an H residue at position 1; a G residue at position 4, an F residue at position 6; a T residue at position 7 and a D residue at position 9, should be included in a fragment since these residues are highly conserved and are important for receptor binding. Thus, additional fragments or modified sequences can be easily made that exclude or alter amino acids of GLP-1 and exendin-4, other than these 5. Because the differentiation activity disclosed herein is easy to assess, the determination that a fragment is within the scope of the invention is routine.